Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinib is a targeted drug that is mainly used to treat cholangiocarcinoma.How many versions of Pemigatinib are there?From the perspective of drug specifications, Pemigatinib i···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：273
Capmatinib is a lung cancer drug that targets specific genetic mutations, especially for patients with non-small cell lung cancer with METex14 skipping mutations. The drug helps to···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：329
Pemigatinibis a targeted drug for the treatment of cholangiocarcinoma and belongs to the FGFR (fibroblast growth factor receptor) inhibitor class.What is Pemigatinib?Pemigatinibis ···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：273
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer harboring mutations in MET exon 14. It helps patients control the spread of pathological cells by i···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：329
Exkivity reduces the growth of non-small cell lung cancer by binding to and inhibiting EGFR exon 20 insertion mutations.What interactions can occur with other medicationsExkivity m···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：298
Exkivity works by binding to and blocking EGFR exon 20 insertion mutations, which helps to slow the growth of cancer cells.Which drugs interact with ExkivityExkivity may interact w···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：313
Exkivity was granted accelerated FDA approval in 2021 based on results from the clinical trial NCT02716116. It is used with the Oncomine Dx Target Test, which identifies patients w···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：343
Exkivity capsules can be used by adults with non-small cell lung cancer that has spread to other parts of the body (metastatic) and cannot be removed with surgery, whose disease ha···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：245
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation.What does Mobotinib pay attenti···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：274
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation. Exkivity reduces the growth of···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：269
Capmatinib targets the activity of MET receptors and blocks the tumor cell growth signaling pathway driven by MET receptors, enabling effective treatment for patients with non-smal···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：341
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-competitive properties, which can significantly inhibit the proliferation and migration ability of c-Met···【more】
Article source：Captain MedicineRelease date：2024-08-08Recommended：324
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4532024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2322025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2452025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2252025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2352025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2162025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
